Rubicon Organics Clears Cascadia for International Medical Cannabis

Rubicon Organics has certified its second British Columbia cultivation facility for international medical cannabis export markets, with both of the company’s growing sites now cleared for supply into European and Australian pharmaceutical pipelines. The certification covers the Cascadia indoor facility in Hope, BC — acquired in 2025 and operational since early this year — and follows its flagship Pacifica greenhouse in Delta, which cleared a comparable cultivation-quality certification through international body Control Union in February 2025.

What the Certification Unlocks

The standard at issue — Good Agricultural and Collection Practices, or GACP — governs how cannabis is grown, harvested, and handled at the farm level for regulated medical markets. It applies specifically to the agricultural stage of production. Downstream from the farm, European and Australian medical cannabis importers typically require source-farm GACP certification before cannabis biomass can enter their own Good Manufacturing Practices-certified facilities for processing into finished pharmaceutical-grade products.

Canada’s export framework adds a layer on top. Under the Cannabis Act and its regulations, Health Canada issues individual export permits on a per-shipment basis, only for medical or scientific purposes. GACP compliance doesn’t bypass that process — every shipment still requires Health Canada sign-off through the federal Cannabis Tracking and Licensing System. But GACP is what importing markets require on their end; without it, there’s no licensed buyer authorized to accept the shipment under pharmaceutical import rules.

For Pacifica, the 2025 certification — an IMC-G.A.P. Equivalency standard from Control Union that demonstrates compliance with World Health Organization and European Medicines Agency GACP guidelines — opened Rubicon’s path to those international markets. The Cascadia certification brings the newer facility to the same threshold, meaning the company can draw on both sites when supplying international customers.

From First Harvest to Export-Ready

Cascadia has moved through its milestones quickly. The facility cleared its Health Canada cultivation license in October 2025, completed its first harvest in February 2026, and is now described as fully planted and operational. At 47,500 square feet, it adds an estimated 4,500 kilograms of annual production capacity — roughly a 40 percent increase over Rubicon’s total output before the acquisition — with production quality targeting the same premium-brand standard as Pacifica.

CEO Margaret Brodie framed the certification around supply reliability for international buyers. “Achieving GACP certification at Cascadia is a testament to the rigorous standards we have embedded across our cultivation operations,” she said. “This milestone strengthens our ability to reliably supply international medical markets as we continue to expand our international reach.”

The certification confirms that Cascadia meets requirements for product consistency, contamination control, traceability, and documentation — the front-end quality record European and Australian regulators expect to see documented before their processors accept incoming cannabis biomass.

International as a Growth Layer

Rubicon’s domestic business has been on a consistent growth track. Its 1964 Supply Co. brand held the top position among premium cannabis brands sold in Canada in 2025, and the company’s SEDAR+ financial filings show third-quarter 2025 net revenue of $15.6 million, up 16 percent year-over-year, against nine-month 2025 revenue of $43.0 million — a 25 percent increase over the same period in 2024. Adjusted EBITDA for the third quarter came in at $1.7 million.

The international medical push is structurally different from the brand retail side. The company launched 1964 Supply Co. in the United Kingdom earlier in 2026 — its first international consumer market entry — but the Cascadia GACP certification is about the pharmaceutical supply chain: premium cannabis biomass flowing from certified BC cultivation sites into EU and Australian GMP processing facilities for medical products.

Larger Canadian licensed producers have pursued international medical as a meaningful revenue line for years. Aurora Cannabis (ACB ) built its forward strategy around it; Tilray (TLRY ) has expanded its medical portfolio into Australia; Organigram (OGI ) has moved product toward European distributors. For Rubicon, a smaller premium producer with strong domestic brand economics, the case is that indoor premium cultivation quality translates into those markets, where tighter regulatory requirements and the pharmaceutical channel support better margins than domestic recreational.

Rubicon hasn’t disclosed specific international medical partners or announced volume commitments at either facility. What the Cascadia certification does is remove a structural constraint: the company now has more certified cultivation capacity to put toward those contracts if they develop.